Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Third Time Is The Charm For ReGen’s Knee Repair Collagen Scaffold

This article was originally published in The Gray Sheet

Executive Summary

ReGen Biologics plans a February U.S. launch of its Menaflex collagen knee cartilage repair product at the 2009 American Academy of Orthopedic Surgeons meeting in Las Vegas now that FDA has signed off on the product after several years of resistance

You may also be interested in...



Do-Over? FDA Orders Look-Back At Knee Device 510(k) Review Process

In a sign of the intense scrutiny CDRH is facing under the new administration, FDA is taking the rare step of performing an internal review of its decision process for a recently 510(k)-cleared device. The inquiry could potentially lead to a "reconsideration" of the clearance, the agency says

Do-Over? FDA Orders Look-Back At Knee Device 510(k) Review Process

In a sign of the intense scrutiny CDRH is facing under the new administration, FDA is taking the rare step of performing an internal review of its decision process for a recently 510(k)-cleared device. The inquiry could potentially lead to a "reconsideration" of the clearance, the agency says

Device Center Discord: 510(k) Review Process Is Flash Point At CDRH

Details trickling into the public sphere about CDRH's device review process reveal heightened tension between reviewers and management over the proper response to a 510(k) submission

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT026957

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel